Semaglutide

In human trials

• See source wording

  under the skin · weekly

  The Impact of Semaglutide Compared to Energy Restriction on Type 2 DiabetesPHASE4 · NCT07272343

  “The semaglutide group received weekly subcutaneous semaglutide (0.25 mg for weeks 1-2, 0.5 mg for weeks 3-4, and 1.0 mg for weeks 5-12)..”

• See source wording

  weekly

  Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTsNA · NCT07589322

  “Starting at Tirzepatide 2.5 mg weekly and escalated as tolerated to 10 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials..”

• See source wording

  under the skin

  A Study of HS-20094 in T2DM ParticipantsPHASE2 · NCT06118008

  “HS-20094 5mg.”

• See source wording

  under the skin · once a week · for 4 weeks

  Treatment to Regress to Normoglycemia in Women with a Recent History of GDMPHASE4 · NCT04873050

  “Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses.”

• 2.4 mg

  under the skin · weekly · for 5 weeks

  A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With ObesityPHASE1 · NCT03842202

  “Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks..”

• See source wording

  by mouth · daily

  Efficacy of Oral Semaglutide in Overweight or ObesityPHASE4 · NCT05442450

  “Treatment will be initiated with the 3 mg once-daily dose.”

• 50 mg

  by mouth · once daily · for 68 weeks

  Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With ObesityPHASE3 · NCT05132088

  “semaglutide 50 mg.”

• 2.4 mg

  Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsPHASE3 · NCT07150975

  “Semaglutide(Wegovy® )2.4 mg”

• See source wording

  under the skin · weekly · for 2 weeks

  Mechanisms of Semaglutide Therapy in Heart Failure PatientsPHASE1, PHASE2 · NCT06541509

  “After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks.”

• 2.4 mg

  under the skin · weekly

  A Research Study on How Well Semaglutide Works in Adolescents With Overweight or ObesityPHASE3 · NCT04102189

  “2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly.”

• See source wording

  under the skin · single dose · for 4 weeks

  First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With DiabetesPHASE1 · NCT04259801

  “Part 1: Single dose of semaglutide (0.5 mg).”

• 1 mg

  under the skin · weekly

  Semaglutide in CFRDPHASE2, PHASE3 · NCT05788965

  “Semaglutide 1 mg once weekly subcutaneous injection”

• See source wording

  under the skin · weekly

  A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightPHASE3 · NCT06131437

  “CagriSema 2.4 mg/2.4 mg.”

• See source wording

  under the skin · weekly · for 12 weeks

  A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesPHASE3 · NCT06894784

  “Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.”

• See source wording

  weekly · for 2 month

  Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational DiabetesPHASE3 · NCT05569772

  “maintenance dose of 1mg SC once weekly.”

• See source wording

  weekly · for 4 weeks

  16-week Flexible vs. 8-week Semaglutide TitrationPHASE3 · NCT04447859

  “eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy).”

• See source wording

  under the skin · weekly · for 4 weeks

  Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani AdultsPHASE4 · NCT07513168

  “Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg).”

• See source wording

  under the skin · every 4 weeks

  Effect of Subcutaneous Semaglutide on Kidney Transplant CandidacyPHASE3 · NCT04741074

  “Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution.”

• See source wording

  weekly

  Semaglutide in Comorbid Schizophrenia Spectrum Disorder and ObesityNA · NCT05333003

  “The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week.”

• See source wording

  under the skin · once daily · for 4 weeks

  Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and AlbuminuriaPHASE4 · NCT04061200

  “Semaglutide, 1.34 mg/mL.”

• See source wording

  under the skin · once a week

  A Study of BGM0504 in Participants with Type 2 DiabetesPHASE3 · NCT06716216

  “Drug: 5 mg BGM0504 Administered SC.”

• See source wording

  by mouth · for 3 months

  Sit Less, Interact and Move More (SLIMM) 2 StudyPHASE2 · NCT05173714

  “Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period..”

• See source wording

  under the skin · weekly · for 4-6 weeks

  SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerPHASE4 · NCT07462663

  “Typical regimens include medroxyprogesterone acetate (400-600 mg/day) or megestrol acetate (160-320 mg/day).”

• 0.25 mg

  single dose

  A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and ObesityPHASE2 · NCT04143945

  “Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day.”

• See source wording

  by mouth · daily

  A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With ObesityPHASE4 · NCT07728383

  “Semaglutide 6 mg liquid emulsion formulation.”

• See source wording

  under the skin · once a week

  A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaPHASE3 · NCT07064486

  “5 mg BGM0504.”

• 1 mg

  under the skin · weekly

  A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesPHASE3 · NCT06649344

  “Semaglutide-1mg”

• See source wording

  under the skin · every 4 weeks · for 24 weeks

  A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate FormulationsPHASE1 · NCT05766709

  “NNC0194-0499/Semaglutide A (40/3.20 mg/mL).”

• 2.4 mg

  under the skin · weekly · for 52 weeks

  Research Study Looking at How Well Semaglutide Works in People Living With Obesity and PrediabetesPHASE3 · NCT05040971

  “Semaglutide 2.4 mg.”

• See source wording

  under the skin · weekly · for 1 month

  Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 DiabetesPHASE2 · NCT06762314

  “will include 35 patients who in addition to insulin (basal/bolus) will receive semaglutide 0.25 mg Sc once weekly for 1 month then increase to 0.5 mg SC once weekly for 2 months..”

• See source wording

  under the skin · weekly

  Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction TendenciesNA · NCT07732426

  “Participants receive an 8-week subcutaneous semaglutide dose-escalation treatment using Wegovy: 0.25 mg once weekly for the first 4 weeks, followed by 0.5 mg once weekly for the next 4 weeks..”

• See source wording

  under the skin · weekly · for 16 weeks

  Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical TrialPHASE4 · NCT07732218

  “smaglutide was initiated at 0.25mg once weekly for the first 4 weeks, followed by 0.5mg once weekly for the subsequent 12 weeks.”

• See source wording

  under the skin · weekly · for 52 weeks

  A Study of BGM0504 in Early T2DM With ObesityPHASE3 · NCT07743983

  “BGM0504 Injection 15 mg.”

• See source wording

  under the skin · once daily

  Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 DiabetesNA · NCT07599046

  “Semaglutide (1 Mg Dose).”

• See source wording

  under the skin · weekly · for 16 weeks

  Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)PHASE4 · NCT04979130

  “Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk..”

• See source wording

  for 4 weeks

  A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young AdultsNA · NCT07364175

  “2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks.”

• 1 mg

  under the skin · weekly

  Feasibility of Semaglutide in Advanced Lung DiseasePHASE1, PHASE2 · NCT05746039

  “Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy”

• See source wording

  under the skin · single dose

  A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) DosePHASE1 · NCT05689099

  “Semaglutide B, 1.34 mg/mL.”

• See source wording

  by mouth · once daily · for 68 weeks

  Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 DiabetesPHASE3 · NCT04707469

  “Oral semaglutide 50 mg.”

• See source wording

  under the skin · weekly · for 8 weeks

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)PHASE3 · NCT05259033

  “Semaglutide 1 mg.”

• See source wording

  under the skin

  Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of SemaglutidePHASE1 · NCT02231684

  “under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL)..”

• 50 mg

  by mouth · daily · for 7 days

  Effect of Itopride on Semaglutide GastroparesisPHASE4 · NCT07254715

  “Itopride HCI 50 mg.”

• See source wording

  by mouth · once daily

  Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 DiabetesPHASE1 · NCT01324505

  “One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg..”

• See source wording

  under the skin

  A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of SemaglutidePHASE1 · NCT04228354

  “Semaglutide 0.68 mg/mL.”

• 1.34 mg/ml

  under the skin · for 26 weeks

  Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNot stated · NCT05689372

  “Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks.”

• See source wording

  weekly

  Semaglutide Use in Elderly Obese PatientsPHASE2 · NCT05302596

  “semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program.”

• See source wording

  under the skin · weekly · for 3-6 months

  Preoperative Semaglutide Prior to Radical ProstatectomyEARLY_PHASE1 · NCT07727473

  “Semaglutide 2.4 mg.”

• See source wording

  A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese MenPHASE1 · NCT05498610

  “1.7 mg NNC0408-0389 plus 0.5 mg semaglutide.”

• See source wording

  under the skin · weekly

  Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial HyperplasiaPHASE2 · NCT05829460

  “Dosing will be escalated during weeks 1 through 16 (start at 0.25 mg up to 2.4 mg).”

• See source wording

  by mouth · once daily

  Combined Active Treatment in Type 2 Diabetes With NASHPHASE4 · NCT04639414

  “Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector.”

• See source wording

  weekly

  GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DMPHASE4 · NCT07314684

  “The starting dose is 0.25 mg semaglutide once weekly.”

• 1 mg

  weekly

  ADJUnct Semaglutide Treatment in Type 1 DiabetesPHASE2 · NCT05537233

  “Semaglutide up to 1 mg per week in addition to standard closed-loop therapy.”